Eagle Total Stockholder Equity vs Non Current Liabilities Total Analysis
EGRX Stock | USD 4.16 0.08 1.89% |
Eagle Pharmaceuticals financial indicator trend analysis is much more than just examining Eagle Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eagle Pharmaceuticals is a good investment. Please check the relationship between Eagle Pharmaceuticals Total Stockholder Equity and its Non Current Liabilities Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
Total Stockholder Equity vs Non Current Liabilities Total
Total Stockholder Equity vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eagle Pharmaceuticals Total Stockholder Equity account and Non Current Liabilities Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Eagle Pharmaceuticals' Total Stockholder Equity and Non Current Liabilities Total is 0.78. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Eagle Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eagle Pharmaceuticals' Total Stockholder Equity and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Eagle Pharmaceuticals are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Total Stockholder Equity i.e., Eagle Pharmaceuticals' Total Stockholder Equity and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Non Current Liabilities Total
Most indicators from Eagle Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 31.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.25 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.6M | 4.0M | 4.7M | 4.9M | Depreciation And Amortization | 3.8M | 12.0M | 13.8M | 14.5M |
Eagle Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eagle Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eagle Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 254.6M | 253.2M | 253.7M | 406.2M | 467.1M | 490.4M | |
Short Long Term Debt Total | 38.6M | 37.1M | 25.6M | 62.5M | 71.8M | 41.6M | |
Other Current Liab | 2.3M | 3.1M | 7.0M | 85.8M | 98.7M | 103.7M | |
Total Current Liabilities | 38.8M | 38.1M | 74.4M | 111.1M | 127.8M | 134.1M | |
Total Stockholder Equity | 179.2M | 186.0M | 176.5M | 233.6M | 268.6M | 138.0M | |
Property Plant And Equipment Net | 2.2M | 2.1M | 1.6M | 1.2M | 1.3M | 2.3M | |
Current Deferred Revenue | 21.7M | 26.1M | 20.7M | 25.4M | 29.2M | 17.3M | |
Net Debt | (71.2M) | (66.1M) | (72.1M) | 7.1M | 6.4M | 6.8M | |
Retained Earnings | 72.5M | 84.5M | 75.9M | 111.5M | 128.2M | 134.6M | |
Accounts Payable | 5.5M | 6.3M | 16.4M | 19.0M | 21.8M | 22.9M | |
Cash | 109.8M | 103.2M | 97.7M | 55.3M | 63.6M | 73.0M | |
Non Current Assets Total | 75.1M | 87.1M | 81.1M | 217.4M | 250.0M | 262.5M | |
Non Currrent Assets Other | 3.9M | 5.0M | 4.2M | 15.7M | 18.1M | 19.0M | |
Other Assets | 13.9M | 32.4M | 29.1M | 52.9M | 60.8M | 63.9M | |
Long Term Debt | 38.2M | 33.6M | 25.1M | 56.2M | 64.6M | 67.9M | |
Cash And Short Term Investments | 109.8M | 103.2M | 97.7M | 55.3M | 63.6M | 75.1M | |
Net Receivables | 48.0M | 51.1M | 41.1M | 72.4M | 83.3M | 87.5M | |
Common Stock Shares Outstanding | 14.1M | 13.8M | 13.1M | 13.1M | 15.0M | 14.9M | |
Liabilities And Stockholders Equity | 254.6M | 253.2M | 253.7M | 406.2M | 467.1M | 490.4M | |
Non Current Liabilities Total | 36.6M | 29.1M | 2.9M | 61.5M | 70.7M | 74.3M | |
Inventory | 6.6M | 8.1M | 21.9M | 47.8M | 55.0M | 57.7M | |
Other Current Assets | 15.1M | 1.6M | 11.9M | 13.2M | 15.2M | 8.2M | |
Other Stockholder Equity | 106.7M | 101.5M | 100.7M | 123.2M | 110.8M | 100.8M | |
Total Liab | 75.4M | 67.2M | 77.3M | 172.6M | 198.5M | 208.4M | |
Property Plant And Equipment Gross | 2.2M | 2.1M | 7.6M | 7.8M | 8.9M | 9.4M | |
Total Current Assets | 179.4M | 166.1M | 172.6M | 188.8M | 217.1M | 137.0M | |
Short Term Debt | 6.3M | 5M | 8M | 25.6M | 7.2M | 8.4M | |
Property Plant Equipment | 2.2M | 2.1M | 1.6M | 1.2M | 1.3M | 2.3M | |
Net Tangible Assets | 123.8M | 133.4M | 126.0M | 70.2M | 80.7M | 106.8M | |
Retained Earnings Total Equity | 72.5M | 84.5M | 75.9M | 111.5M | 128.2M | 134.6M | |
Capital Surpluse | 278.5M | 305.4M | 325.8M | 366.3M | 421.2M | 282.9M | |
Treasury Stock | (171.9M) | (203.9M) | (225.1M) | (243.1M) | (218.8M) | (207.9M) | |
Intangible Assets | 15.6M | 12.9M | 10.7M | 118.3M | 136.1M | 142.9M |
Pair Trading with Eagle Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eagle Stock
0.7 | VTRS | Viatris Earnings Call This Week | PairCorr |
0.69 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Eagle Stock
0.81 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
0.79 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
0.62 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
0.45 | HCM | HUTCHMED DRC | PairCorr |
The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.
The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.